443-15D3-2F12 [15D3, CMCC 10748] (ATCC® HB-11342)

Organism: Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma)  /  Cell Type: hybridoma: B lymphocyte  / 

Permits and Restrictions

View Permits

Organism Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma)
Cell Type hybridoma: B lymphocyte
Product Format frozen
Morphology lymphoblast
Culture Properties suspension
Biosafety Level 1

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Strain

Strain: BALB/c (B cell); BALB/c (myeloma)

Applications
Animals were immunized with BALB/c 3T3 fibroblast cells, which were transfected with the human MDR1 gene and then selected for the drug resistance phenotype by growth in vinblastine-containing culture medium.
The antibody may be useful for diagnostic detection of MDR in patients undergoing chemotherapy or as targeting components of immunotherapeutic agents.
Disclosure This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC.
Derivation
Spleen cells were fused with Sp2/0-Ag14 mouse myeloma cells.
Clinical Data
The antibody may be useful for diagnostic detection of MDR in patients undergoing chemotherapy or as targeting components of immunotherapeutic agents.
Genes Expressed
immunoglobulin; monoclonal antibody; against the human multi-drug resistance antigen, P-glycoprotein
Cellular Products
immunoglobulin; monoclonal antibody; against the human multi-drug resistance antigen, P-glycoprotein
Comments
Animals were immunized with BALB/c 3T3 fibroblast cells, which were transfected with the human MDR1 gene and then selected for the drug resistance phenotype by growth in vinblastine-containing culture medium.
Spleen cells were fused with Sp2/0-Ag14 mouse myeloma cells.
The murine hybridoma 15D3 recognizes the human multi-drug resistance antigen, P-glycoprotein.
The antibody immunoprecipitates a 170- to 180-kDa protein from multi-drug resistance (MDR) cells, but does not block binding of the known anti-P-glycoprotein antibody MRK16.
The antibody may be useful for diagnostic detection of MDR in patients undergoing chemotherapy or as targeting components of immunotherapeutic agents.
The hybrid hybridoma cell lines 1B7 (ATCC HB-10500) and 1A7 (ATCC HB-10501) were formed by the fusion of the 15D3 (ATCC HB-11342) and 3G8 hybridoma cell lines.
Complete Growth Medium The base medium for this cell line is ATCC-formulated Iscove's Modified Dulbecco's Medium, Catalog No. 30-2005. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Subculturing
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)
Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 to 2 X 10 exp5 viable cells/ml.
Maintain cell density between 1 X 10 exp5 and 1 X 10 exp6 viable cells/ml.
Cryopreservation
culture medium 95%; DMSO, 5%
Culture Conditions
Temperature: 37.0°C
Isotype IgG1; kappa light chain
Name of Depositor Chiron Corp.
Deposited As mouse (B cell); mouse (myeloma)
U.S. Patent Number
Disclosure This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC.
References

Ring D, Shi TX. Monoclonal anti-multiple drug resistance antibody, methods of production and uses thereof. US Patent 6,143,873 dated Nov 7 2000

Ring D, Shi TX. Bispecific antibodies, methods of production and uses thereof. US Patent 5,959,084 dated Sep 28 1999

Ring D, Shi TX. Bispecific antibodies, methods of production and uses thereof. US Patent 6,106,833 dated Aug 22 2000

Ring DB. Nucleic acids encoding antigen-binding sites specific for cancer antigens. US Patent 5,948,647 dated Sep 7 1999

Ring DB. Isolated nucleic acid molecules encoding antigen binding sites of antibody molecules specific for cancer. US Patent 5,811,267 dated Sep 22 1998

Shi T, et al. High-affinity monoclonal antibodies against P-glycoprotein. Clin. Immunol. Immunopathol. 76: 44-51, 1995. PubMed: 7541735

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
References

Ring D, Shi TX. Monoclonal anti-multiple drug resistance antibody, methods of production and uses thereof. US Patent 6,143,873 dated Nov 7 2000

Ring D, Shi TX. Bispecific antibodies, methods of production and uses thereof. US Patent 5,959,084 dated Sep 28 1999

Ring D, Shi TX. Bispecific antibodies, methods of production and uses thereof. US Patent 6,106,833 dated Aug 22 2000

Ring DB. Nucleic acids encoding antigen-binding sites specific for cancer antigens. US Patent 5,948,647 dated Sep 7 1999

Ring DB. Isolated nucleic acid molecules encoding antigen binding sites of antibody molecules specific for cancer. US Patent 5,811,267 dated Sep 22 1998

Shi T, et al. High-affinity monoclonal antibodies against P-glycoprotein. Clin. Immunol. Immunopathol. 76: 44-51, 1995. PubMed: 7541735